Warfarin and aspirin are similar in heart failure treatment

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

"Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University in New York.

In the 11-country Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, researchers followed 2,305 patients with heart failure and normal heart rhythm for up to six years (average 3.5 years). The patients were on average 61 years old, and the power of the heart's main pumping chamber, the left ventricle (left ventricular ejection fraction), was less than 35 percent (normal is 55 percent or higher).

Thirteen percent of the patients experienced a stroke or transient ischemic attack and were at heightened risk of recurrence. Patients with heart failure in general are at increased risk of death, blood clots and strokes.

Researchers randomly assigned patients to receive either 325 mg/day of aspirin or warfarin doses calibrated to a pre-specified level of blood thinning. Warfarin therapy requires frequent blood testing to monitor its dosage in order to achieve the desired level of blood thinning. In order to avoid bias, all patients had blood drawn on the same schedule and their pills adjusted so neither the patients nor their treating physicians knew which regimen they were taking.

Death, ischemic stroke (caused by blockage of an artery feeding the brain) or intracerebral hemorrhage (bleeding inside the brain), which combined were the study's primary endpoint, occurred at a rate of 7.47 percent for patients assigned to warfarin and 7.93 percent for patients assigned to aspirin. The difference was not statistically significant.

However, "in the group of patients followed for more than three years, those on warfarin did better in comparison to the aspirin patients," Homma said. Over the entire study period, patients receiving warfarin were just over half as likely to develop a stroke, a component of primary endpoint, as those taking aspirin. The rates of stroke were low with annual rates of 0.72 percent in patients assigned to warfarin and 1.36 percent for those on aspirin.

Researchers evaluated the safety of the anti-clotting medications by monitoring major bleeding events other than intracerebral hemorrhage (which was a component of the primary endpoint). Each year, major bleeds occurred in 1.8 percent of patients on warfarin and 0.9 percent of those on aspirin - a statistically significant difference.

"As expected, the overall bleeding rate was higher with warfarin," Homma said. "However, not all bleeds are equal, and the one that patients fear the most - bleeding within the brain (intracerebral hemorrhage) occurred rarely in both groups." It occurred in 0.12 percent per year in the warfarin group and 0.05 percent per year in the aspirin group.

"Given that there is no overall difference between the two treatments and that possible benefit of warfarin does not start until after 4 years of treatment, there is no compelling reason to use warfarin, especially considering the bleeding risk", Homma said. The investigators are analyzing whether certain subgroups of patients benefited more from each treatment.

The study's co-author is John L.P. Thompson, Ph.D. and the WARCEF Investigators.

The National Institutes of Health/National Institute of Neurological Disorders and Stroke funded the study.

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...